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Existing treatments for breast cancer are helpful for many patients, but treat-
ment failure remains a common event, and there is a strong clinical need to
improve upon current therapies. Somatostatin analogues have been evaluated
for antineoplastic activity in model systems over the past decade, and encour-
agingresults have beenobtained (reviewedin [1, 2]). Thishas ledto suggestions
to test these agents clinically in the treatment of breast cancer patients, and a
program of clinical trials has recently been initiated. This review will describe
aspects ofresearch in this area.
DIRECT MECHANISM OFACTION
The so-called "direct" mechanism of action of somatostatin analogues in the context
ofbreast cancer treatment refers to inhibition ofproliferation and/or induction ofapopto-
sis, which take place as a consequence of a somatostatin analogue binding to a somato-
statin receptor on abreast cancer cell. Recent evidence [3] supports earlier reports [4] that
documented the presence of somatostatin receptors on primary human breast cancers.
There is now ahighdegree ofconfidence that atleasthalfofhumanbreastcancers express
somatostatin receptors, andithas beenpossible to imageprimary breast cancers andnodal
metastases by somatostatin analogue scintigraphy [3]. There is some suggestion that
somatostatin receptor abundance is greater on well-differentiated, estrogen-receptor posi-
tive tumors than on anaplastic cancers. Work to characterize the abundance ofeach ofthe
five somatostatin receptor subtypes in normal and neoplastic breast epithelial tissue is
ongoing [5].
Evidence that the "direct" mechanism ofaction has relevance forbreast cancer comes
from tissue culture studies that show inhibition of proliferation of clonal populations of
breast cancer cells grown in tissue culture [6]. In most experimental systems (e.g., [6]),
such direct inhibition is maximized in the absence ofestrogens, and this has led to the pro-
posal that the effect of somatostatin analogues on breast cancers in vivo might be maxi-
mized if they were co-administered with agents such as antiestrogens or aromatase
inhibitors.
In recent years, there has been important progress in understanding the signal trans-
duction pathways involved in the "direct" mechanism ofaction ofsomatostatin analogues
[7-9]. Forexample, there are data suggesting thatbinding ofsomatostatin or a somatostatin
analogue such as octreotide orRC-160 tothe type 2 somatostatin receptoractivates aphos-
photyrosine phosphatase activity [10]. This is the reciprocal activity ofthe tyrosine kinase
activity associated with many peptide mitogen receptor receptors, such as the epidermal
growth factor (EGF)b receptor or the insulin-like growth factor I (IGF-I) receptor, so it is
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not unexpected that growth inhibition is a consequence of ligand binding to the type 2
somatostatin receptor. Recent evidence [11] is consistent with the existence of a link
between the type 3 somatostatin receptor and a p53-related apoptotic signal transduction
pathway.
INDIRECT MECHANISMS OFACTION
"Indirect" mechanisms of action are those that do not involve an interaction between
somatostatin analogues and neoplastic cells but nevertheless result in inhibition of neo-
plastic behavior. It must be emphasized that for somatostatin-receptor positive neoplasms,
the direct and indirect mechanisms of action of somatostatin analogues are not mutually
exclusive, and both may contribute to any antiproliferative effect seen. On the other hand,
only the indirectmechanisms can have an impacton somatostatin-receptor-negative breast
cancers. One potential indirect mechanism of somatostatin analogues under investigation
involves reduction ofIGF-I bioactivity. In general, IGF-I is a potent mitogen [12, 13] and
inhibitor of apoptosis [14]. There is a large body of data to support the view that IGF-I
influences breast cancer behavior. Not only is IGF-I a potent breast cancer mitogen in
vitro [15, 16], but it has been noted that the growth of breast cancer xenografts can be
reduced by a blocking antibody to the IGF-I receptor [17] and that the proliferation of
human breast cancer xenografts is reduced in hosts that are deficient in IGF-I as a conse-
quence ofthe "lit' mutation [18].
While it has long been recognized that the abnormally high levels of IGF-I seen in
acromegaly can be lowered towards normal by somatostatin analogues, it is also true that
somatostatin analogues suppress the functioning of the normal growth-hormone/IGF-I
axis [19]. This may influence IGF-I-responsive breast cancers. More recent data show that
the antiestrogen tamoxifen has a similar suppressive effect on the growth-hormone/IGF-I
axis, characterized by inhibition ofpituitary growth hormone output [20, 21], reduction of
IGF-I serum levels [22], and reduced expression of IGF-I in target organs for metastasis
[23]. It has been proposed that these effects of tamoxifen contribute to its antineoplastic
action. Interestingly, in breast cancer tissue, IGF-I receptor levels are positively correlat-
ed with estrogen receptor levels [24]. Thus, neoplasms identified on the basis ofestrogen
receptor levels to be likely to respond to antiestrogens are those that are most likely to be
most influenced by reductions of IGF bioactivity. Octreotide [25] and antiestrogens [26,
27] may also reduce IGF bioactivity by separate effects on IGF binding proteins.
It has been proposed [28] that a separate rationale for reducing IGF-I levels in the
management of breast cancer can be derived from epidemiological evidence that breast
cancer incidence is higher and prognosis worse [29-35] in taller as compared to shorter
women, when this information is taken in the context ofthe knowledge that IGF-I level is
a determinant ofheight [36]. This rationale is somewhat controversial: while the associa-
tion between height and breast cancer risk and outcome is reported to be statistically sig-
nificant, it nevertheless is modest in magnitude.
BASIS FOR PROPOSED CLINICAL TRIALS
While preclinical models demonstrate antiproliferative activity of somatostatin ana-
logues in experimental breast cancer, such activity is generally not greater in magnitude
than that of endocrine therapies already in clinical use. Therefore, there has been little
motivation for randomized clinical trials to compare somatostatin analogues as single
agents to other approved endocrine therapies in the first-line treatment of breast cancer.
There have been some uncontrolled studies suggesting that octreotide treatment can be
536Pollak: Somatostatin analogues in breast cancer treatment
useful in salvage therapy ofpatients who failed prior therapies [37], but this has not been
studied in a formal randomized fashion, and the response rates in this setting are not
greater than 20 percent.
However, recent experimental results demonstrate greater antineoplastic activity of
tamoxifen combined with octreotide than of single-agent tamoxifen or single-agent
octreotide [38]. Laboratory research provides at least two plausible mechanisms underly-
ing this observation. First, it is possible that any direct effect of octreotide on breast can-
cer is amplified in the presence of antiestrogens, as it has been observed that the antipro-
liferative effects of octreotide are attenuated in the presence of estradiol. Second, in the
context of the data that both tamoxifen [22] and octreotide [19] have actions that would
be expected to reduce IGF-I bioactivity, there is laboratory [39] and clinical [40] evidence
that such reduction is greater when the two agents are co-administered than when they are
given individually. These rationales for co-administration of antiestrogens and octreotide
are not mutually exclusive.
In view of the preclinical data [38], there is considerable interest in comparing stan-
dard tamoxifen therapy to the combination of tamoxifen and octreotide with respect to
efficacy and toxicity. Clinical trials to examine this issue will be practical because of the
recent availability of a monthly depot formulation of octreotide. One clinical setting for
such a trial is in the treatment ofpatients with previously untreated macroscopic metasta-
tic disease. Another setting is in the adjuvant treatment ofbreast cancer. This refers to the
treatment of apparently disease-free women who may have micrometastatic disease dur-
ing the post-surgical period, with the objective of reducing the rate of relapse and pro-
longing disease-free survival. In both the adjuvant and metastatic settings, tamoxifen is
known to have beneficial effects, yet there is substantial room for improvement in the effi-
cacy oftherapy. Only carefully controlled clinical trials will establish whether the labora-
tory clues concerning somatostatin analogues reviewed here will translate into improve-
ments in the treatment ofbreast cancer.
As of January 1997, two clinical trials in this area have been initiated. An interna-
tional European-based trial is randomizing patients with measurable metastatic breast can-
cer that has not been previously treated to therapy with either tamoxifen or the tamoxifen
-octreotide combination. Clinical endpoints will involve response rate and response dura-
tion. A recently activated Canadian trial is carrying out a similar randomized comparison
of 800 breast cancer patients, but this trial will be carried out in the post-operative adju-
vant setting for women with stage I or stage II breast cancer, with the major clinical end-
point being relapse-free survival. This trial will also examine outcome in the context of
the effects of each treatment arm on IGF physiology and the somatostatin receptor status
ofthe tumors. Finally, a 2000patient adjuvant study similar to the Canadian studybut con-
fined to relatively good prognosis stage I breast cancer patients is being planned in the
USA. While prior studies have provided data consistent with a favorable toxicity profile
for octreotide, these trials will allow forthe first time adetailed survey ofpotential adverse
effects (such as cholelithiasis) in a large non-acromegalic, non-neuroendocrine tumor
patient population.
Together, these studies will represent one of the largest clinical research programs
ever undertaken with a somatostatin analogue. This research program represents an inter-
esting case-study in rapid translation of preclinical data to a clinical trial program, with
less than three years elapsing between the in vivo preclinical results [38] and the launch-
ing of randomized clinical trials. This can be attributed in part to close collaboration
between industry, academic clinician-scientists and clinical trials organizations.
The preclinical data focus particular attention on the adjuvant trials, as laboratory
studies imply that antineoplastic activity of octreotide is greatest when the tumor burden
is small. These trials will not yield clinical outcome databefore 2000, but will be followed
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with considerable interest in view of the strong clinical need to improve the efficacy of
adjuvant therapy for breast cancer. Given the high incidence of this illness, should these
trials document a favorable influence of octreotide on clinical endpoints, use ofthe com-
pound for this new indication would clearly exceed use for current indications such as
acromegaly and carcinoid syndrome. This would motivate other studies not only to refine
therapy with somatostatin analogues but also to explore other peptide drug candidates in
oncology.
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